Eli Lilly and Company logo

Eli Lilly and Company (LLY)

Market Closed
2 Mar, 20:00
NYSE NYSE
$
1,017. 97
-34.02
-3.23%
$
970.55B Market Cap
104.2 P/E Ratio
6% Div Yield
3,082,237 Volume
6.64 Eps
$ 1,051.99
Previous Close
Day Range
1,013.01 1,056.2
Year Range
623.78 1,133.95
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
LLY earnings report is expected in 57 days (29 Apr 2026)

Summary

LLY closed today lower at $1,017.97, a decrease of 3.23% from yesterday's close, completing a monthly decrease of -2.24% or $23.31. Over the past 12 months, LLY stock lost -5.72%.
LLY pays dividends to its shareholders, with the most recent payment made on Dec 10, 2025. The next announced payment will be in In 1 week on Mar 10, 2026 for a total of $1.73.
The last earnings report, released on Feb 11, 2026, exceeded the consensus estimates by 0.37%. On average, the company has fell short of earnings expectations by -4.71%, based on the last three reports. The next scheduled earnings report is due on Apr 29, 2026.
Eli Lilly and Company has completed 4 stock splits, with the recent split occurring on Oct 16, 1997.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NYSE (USD).

LLY Chart

Similar

AbbVie Inc.
$ 234.26
+0.94%
NVS
Novartis AG Sponsored ADR
$ 166.87
-1.04%
UNH
UnitedHealth Group Incorporated
$ 294.93
+0.57%
AstraZeneca PLC
$ 203.73
-2.26%
ABT
Abbott Laboratories
$ 114.12
-1.92%
Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Seekingalpha | 3 hours ago
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata

LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata

Eli Lilly wins CHMP backing to expand Olumiant use in adolescents with severe alopecia areata, with the EU approval decision expected shortly.

Zacks | 8 hours ago
What Smart Money Loves About Lilly

What Smart Money Loves About Lilly

Eli Lilly (NYSE: LLY) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors have been accumulating shares during the pullback, according to recent filings.

247wallst | 11 hours ago

Eli Lilly and Company (LLY) FAQ

What is the stock price today?

The current price is $1,017.97.

On which exchange is it traded?

Eli Lilly and Company is listed on NYSE.

What is its stock symbol?

The ticker symbol is LLY.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 6%.

What is its market cap?

As of today, the market cap is 970.55B.

When is the next earnings date?

The next earnings report will release on Apr 29, 2026.

Has Eli Lilly and Company ever had a stock split?

Eli Lilly and Company had 4 splits and the recent split was on Oct 16, 1997.

Eli Lilly and Company Profile

Pharmaceuticals Industry
Healthcare Sector
Mr. David A. Ricks CEO
NYSE Exchange
532457108 CUSIP
BR Country
50,000 Employees
10 Mar 2026 Last Dividend
16 Oct 1997 Last Split
13 Jan 1978 IPO Date

Overview

Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.

Products and Services

  • Diabetes Care

    Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.

  • Oncology

    Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.

  • Immunology

    Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

  • Digestive Diseases

    Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.

  • Neurological Disorders

    Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.

  • Other Therapeutic Areas

    The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.

Contact Information

Address: Lilly Corporate Center, Indianapolis, IN, United States, 46285
Phone: 317 276 2000